Intersect ENT (Intersect ENT) FCF Margin % : -125.21% (As of Mar. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Intersect ENT FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Intersect ENT's Free Cash Flow for the three months ended in Mar. 2022 was $-27.0 Mil. Intersect ENT's Revenue for the three months ended in Mar. 2022 was $21.6 Mil. Therefore, Intersect ENT's FCF Margin % for the quarter that ended in Mar. 2022 was -125.21%.

As of today, Intersect ENT's current FCF Yield % is -7.54%.

The historical rank and industry rank for Intersect ENT's FCF Margin % or its related term are showing as below:

XENT' s FCF Margin % Range Over the Past 10 Years
Min: -68.53 Med: 0 Max: 0
Current: -68.53

XENT's FCF Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -7.14 vs XENT: -68.53

Intersect ENT FCF Margin % Historical Data

The historical data trend for Intersect ENT's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intersect ENT FCF Margin % Chart

Intersect ENT Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

FCF Margin %

Get a 7-Day Free Trial

-10.72

-14.71

-28.38

-45.39

-57.60

Intersect ENT Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
FCF Margin %	Get a 7-Day Free Trial															-70.86	-51.25	-57.39	-52.92	-125.21

Competitive Comparison of Intersect ENT's FCF Margin %

For the Medical Devices subindustry, Intersect ENT's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intersect ENT's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Intersect ENT's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Intersect ENT's FCF Margin % falls into.

Intersect ENT FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Intersect ENT's FCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-61.491	/	106.748
	=	-57.60 %

Intersect ENT's FCF Margin for the quarter that ended in Mar. 2022 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2022 )	/	Revenue (Q: Mar. 2022 )
	=	-27.013	/	21.575
	=	-125.21 %

Intersect ENT FCF Margin % Related Terms

Thank you for viewing the detailed overview of Intersect ENT's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Intersect ENT (Intersect ENT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intersect ENT Inc (NAS:XENT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1555 Adams Drive, Menlo Park, CA, USA, 94025

Website

https://www.intersectent.com

Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.

Executives

Elisabeth Sandoval	director	C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Neil A Hattangadi	director	1555 ADAMS DRIVE MENLO PARK CA 94025
Reyna M Fernandez	officer: Chief Human Resource Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Patrick A Broderick	officer: EVP, GC & Corporate Secretary	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Thomas A. West	director, officer: President and CEO	C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Richard A Meier	officer: EVP & Chief Financial Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Binney Robert H Jr	officer: Vice President, Sales	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Susan P Stimson	officer: Vice President, Marketing	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Lisa D Earnhardt	director, officer: See Remarks	1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Aaron Lehman	officer: General Counsel	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeryl L Hilleman	officer: Chief Financial Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Christine R Kowalski	officer: Chief Operations Officer	C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mead Dana G Jr.	director	2750 SAND HILL ROAD, MENLO PARK CA 94025
Richard E Kaufman	officer: See Remarks	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Gwen R. Carscadden	officer: Chief People Officer	C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025